ArrayExpress Uploader0humanPDprevious ILIM_stage_IIICPDprevious ILIM_stage_IIICPRno previous ILI/ILPF_stage_IIICPRno previous ILI/ILPF_stage_IIICPDprevious ILIF_stage_IIICPDprevious ILIF_stage_IIICPDprevious ILIF_stage_IIICCRno previous ILI/ILPM_stage_IIICCRno previous ILI/ILPM_stage_IIICCRno previous ILI/ILPM_stage_IIICPDprevious vaccine txM_stage_IIIBPDprevious vaccine txM_stage_IIIBSDno previous ILI/ILPF_stage_IIIBSDno previous ILI/ILPF_stage_IIIBCRno previous ILI/ILPF_stage_IIIBCRno previous ILI/ILPF_stage_IIIBSDno previous ILI/ILPM_stage_IIICSDno previous ILI/ILPM_stage_IIICCRprevious ILIF_stage_IIICPDprevious ILIF_stage_IIIBCRno previous ILI/ILPM_stage_IIIBCRno previous ILI/ILPF_stage_IIIBCRno previous ILI/ILPF_stage_IIIBPRno previous ILI/ILPF_stage_IIIBLTF/Uno previous ILI/ILPF_stage_IIICLTF/Uno previous ILI/ILPF_stage_IIICPRno previous ILI/ILPM_stage_IIICPRno previous ILI/ILPM_stage_IIIC3746arrayexpress_sid4An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with ADH-1 followed by melphalan in the...E-GEOD-22968/profile/8773/arrayexpressuploader328diseaselimbmelanomaDec.12, 2014Falsephase-ii-trial-melphalan-ili-plus-adh-1-for-treatmE-GEOD-22968_A-AFFY-44Phase II trial melphalan ILI plus ADH-1 for treatment of in-transit extremity melanomaSep.15, 2014An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with ADH-1 followed by melphalan in the setting of isolated limb infusion Gene expression profiles were obtained from 28 lesions across 15 patients and evaluated for expression values that correlated with ADH-1 treatment given 4-8hrs prior to melphalan isolated limb infusion Chemotherapy response analysis: complete response - CR; partial response - PR; stable disease - SD; progressive disease - PD; lost to follow-up - LTU/F ADH-1 treatment classification: 'pre' - lesions obtained prior to any treatment with ADH-1; 'post' - lesions obtained just prior to ILI with melphalan after 1 treatment with ADH-1; '2nd' - lesions obtained after a 2nd dose of ADH-1 given 8 days after melphalan ILIhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22968http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22968/samples/